Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.omeros.com
Omeros Corporation News Releases
Get the latest updates from Omeros Corporation News Releases directly as they happen.
Follow now 35 followers
Latest posts
Last updated 1 day ago
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025
1 day ago
SEATTLE --(BUSINESS WIRE)--May 12, 2025-- Omeros Corporation (NASDAQ: OMER), today announced that...
Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026
2 days ago
SEATTLE --(BUSINESS WIRE)--May 12, 2025-- Omeros Corporation (Nasdaq: OMER) (“Omeros” or the...
FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date
8 days ago
SEATTLE --(BUSINESS WIRE)--May 6, 2025-- Omeros Corporation (Nasdaq: OMER) today announced that...
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program
about 1 month ago
– The Steering Committee brings together distinguished clinical experts in AML from...
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases
about 1 month ago
-- Targeted Complement Activating Therapy ™ Represents Next-Generation , Broadly Applicable Antimicrobial...
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results
about 1 month ago
– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Mar...
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025
about 2 months ago
SEATTLE --(BUSINESS WIRE)--Mar. 26, 2025-- Omeros Corporation (NASDAQ: OMER), today announced that...
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
about 2 months ago
-- Phase 3 Data Needed for BLA Submission Expected in the Fourth...
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder
2 months ago
– Successful Completion of Animal Drug Interaction Studies Triggers Funding for Phase...
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
3 months ago
– Results Demonstrate Marked Survival Superiority of Narsoplimab-Treated EAP Patients, in Stand-Alone...
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
3 months ago
SEATTLE --(BUSINESS WIRE)--Feb. 14, 2025-- Omeros Corporation (Nasdaq: OMER) today announced the...
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
3 months ago
SEATTLE --(BUSINESS WIRE)--Feb. 10, 2025-- Omeros Corporation (Nasdaq: OMER) today announced two...